Navigation Links
OncoSec to Present at World Cancer Immunotherapy Conference
Date:1/24/2012

DNA-based immuno-cytokine (OMS ElectroImmunotherapy) or chemotherapeutic agent (OMS ElectroChemotherapy). Treatment of various solid cancers using these powerful and targeted anti-cancer agents has demonstrated selective destruction of cancerous cells while sparing healthy normal tissues during early and late stage clinical trials. OncoSec's clinical programs include three Phase II clinical trials for OMS ElectroImmunotherapy targeting lethal skin cancers. More information is available at www.oncosec.com. Additional information may also be found at OncoSec's Facebook, Twitter, and LinkedIn sites.

This press release contains forward looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release that are not historical facts may be considered such "forward looking statements." Forward looking statements are based on management's current preliminary expectations and are subject to risks and uncertainties which may cause our results to differ materially and adversely from the statements contained herein. Some of the potential risks and uncertainties that could cause actual results to differ from those predicted include our ability to raise additional funding, our ability to acquire, develop or commercialize new products, uncertainties inherent in pre-clinical studies and clinical trials, unexpected new data, safety and technical issues, competition and market conditions. These and additional risks and uncertainties are more fully described in OncoSec's filings with the Securities and Exchange Commission. Undue reliance should not be placed on forward looking statements which speak only as of the date they are made. OncoSec disclaims any obli
'/>"/>

SOURCE OncoSec Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoSec to Present at the 22nd Annual Oppenheimer Healthcare Conference
2. OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference
3. OncoSec and Serametrix Collaborate to Identify Potential Biomarkers to Enhance Skin Cancer Immune Therapies
4. OncoSec to Present at Medical Device Investor Forum
5. Device Master File for OncoSec Medical System Completed and Submitted to FDA
6. OncoSec Releases Devices for Use in Clinical Trials
7. Update: OncoSec Announces Positive Results From Head & Neck and Breast Cancer Trials
8. OncoSec Announces Positive Results from Head & Neck and Breast Cancer Trials
9. OncoSec Medical to Attend 6th Annual Fire, Ice and Beyond: The Future of Ablation Therapies Conference
10. OncoSec Medical to Present at Industry and Investor Conferences
11. OncoSec Medical Appoints Engineering Leader
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ... the "Dental Consumables Market - Global Industry ... - 2018" report to their offering. ... ) Dental consumables are products which are ... impairments, for tooth restoration and in treatment of ...
(Date:1/15/2014)... , Jan. 15, 2014  Novation, the leading ... company, awarded several new IT value-added reseller (VAR) ... hospital organizations with IT goods and services at ... agreements, as well as value-added services such as ... New Novation agreements were awarded to ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 ... that it has waived the Office of Fair Trading (OFT) ... the outstanding shares of ViroPharma Incorporated (NASDAQ: VPHM).   ... no longer conditional on OFT approval, and Shire expects to ... currently scheduled expiration time, subject to the satisfaction of all ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3
... Amarin Corporation plc (Nasdaq: AMRN ... the Canaccord Genuity 5th Annual Cardiovascular, Diabetes & Obesity Conference ... will be held at the Nikko Hotel in San Francisco. ... be available at the following URL:   ...
... received 510(k) clearance from the U.S. Food and Drug ... spot scanning. Spot scanning is a proton therapy delivery ... the tumor by using thousands of small individual beamlets ... Intensity Modulated Proton Therapy (IMPT). XiO, Elekta,s ...
Cached Medicine Technology:Amarin to Present at Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference 2Elekta Receives FDA 510(k) Clearance for XiO Software to Plan Spot Scanning for Proton Therapy 2
(Date:4/14/2014)... treat children with uncomplicated acute appendicitis is a reasonable ... fewer missed school days, according to a pilot study. ... Hospital and published online April 12 in the ... the first prospective study on nonoperative management of acute ... , Researchers enrolled 77 patients age 7 to 17 ...
(Date:4/14/2014)... 2014, Perth, Australia. Drug discovery company Proteomics International ... of a companion diagnostic (CDx) test with the ... The research team authenticated the panel of biomarkers ... samples. Seven biomarkers were validated at high stringency ... The mass spectrometry data was then cross-validated using ...
(Date:4/14/2014)... 2014) When it comes to the cost and ... Patients get the best care when they are treated ... extensive experience in their current job, according to a ... and Columbia Business School. The study was published in ... Applied Economics . , The review of more ...
(Date:4/13/2014)... STANFORD, Calif. A low-cost empowerment program for ... and sexual harassment of these girls, who live ... and are frequently attacked, a large new study ... Stanford University School of Medicine, Lucile Packard Children,s ... No Worldwide, validated the program,s effectiveness in combating ...
(Date:4/11/2014)... the processes that control brain cell production could pave ... brain-related disorders. , Scientists have gained new understanding of ... how and when nerve and brain cells are formed ... and keeps it healthy. Their findings could help explain ... which is a fundamental characteristic of many diseases including ...
Breaking Medicine News(10 mins):Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 2Health News:Antibiotics alone are a successful treatment for uncomplicated acute appendicitis in kids 3Health News:Longer nurse tenure on hospital units leads to higher quality care 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 2Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 3Health News:Empowerment program greatly decreases incidence of rape, Stanford/Packard-led study finds 4
... history of snoring, apnea , , WEDNESDAY, June 11 (HealthDay News) ... a sleep-related breathing disorder, says a University of Virginia study. ... to 18 years, who were referred to a pediatric sleep ... an increased frequency of snoring. , The children,s neck size, ...
... been ruled out as source of contaminated tomatoes, they ... health officials said Wednesday they are zeroing in on ... contaminated tomatoes. , "The question is where specifically did ... for foods at the U.S. Food and Drug Administration ...
... Mayo Clinic research suggests unmarried women living in rural ... counterparts. This lower health status often includes greater instances ... study were recently published in the Journal of ... care physicians should take a proactive role in addressing ...
... Case Western Reserve University School of Medicine and Penn ... that reduces sterile inflammation within the cornea. Published in ... Biology, Dr. Eric Pearlman and Dr. Mark Kester ... delivered in nano-sized packages reduces corneal haze, corneal thickening ...
... of some NSAIDS, it could prevent buildup of plaque ... (HealthDay News) -- A class of drugs called gamma-secretase ... study suggests. , A hallmark of Alzheimer,s is so-called ... gamma-secretase modulators reduce the production of long pieces of ...
... Paris, France, Wednesday June 11th 2008: At least 50% ... state free of signs and symptoms) within 36 weeks ... in combination with tight control, according to results of ... Congress of the European League Against Rheumatism in Paris, ...
Cached Medicine News:Health News:Children's Neck Size Associated With Sleep Disorders 2Health News:U.S. Health Officials Closer to Origin of Salmonella Outbreak 2Health News:U.S. Health Officials Closer to Origin of Salmonella Outbreak 3Health News:U.S. Health Officials Closer to Origin of Salmonella Outbreak 4Health News:Mayo Clinic study reveals rural, unmarried women at higher risk for depression 2Health News:New Class of Drugs May Fight Alzheimer's 2Health News:New Class of Drugs May Fight Alzheimer's 3Health News:50 percent of recent onset RA patients become free of signs and symptoms within 36 weeks 2
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
This unit is the finest standalone handswitch bipolar unit available....
...
...
Medicine Products: